drugset / Trial / NCT06940427
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Timeline
- Start
- 2025-11-19
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAPI | Diagnostic / imaging agent | — | Other |